COMMUNIQUÉS West-GlobeNewswire

Assure Holdings Appoints Kelsie Jas as Director of Revenue Cycle Management
29/03/2019
DENVER, March 29, 2019 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, has appointed Kelsie Jas as director of [...]
Statement re Cancellation
29/03/2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION Certain information contained [...]
Passing of Genmab A/S’ Annual General Meeting
29/03/2019
Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2019, the Annual Report for 2018 was approved Discharge was given to the Board of Directors and the Executive Management and the year’s [...]
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
29/03/2019
-First patient enrolled in COMPARE trial evaluating efficacy and safety of SEL-212 v. KRYSTEXXA® in patients with chronic refractory gout -Strengthened management and clinical teams with the appointments of Elona Kogan [...]
World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board
29/03/2019
SAN DIEGO, March 29, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, announced that Dr. Robert Langer, co-inventor of Daré‘s novel, segmented intravaginal ring (IVR) [...]
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
29/03/2019
iTeos Therapeutics Announces Eight Data Presentations for A 2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019 Gosselies, Belgium and Cambridge, MA – March 29, 2019 – iTeos Therapeutics [...]
EMA Grants PRIME Eligibility for KB103 to Treat Dystrophic Epidermolysis Bullosa
29/03/2019
First EMA PRIME eligibility for Krystal Biotech Eligibility based on positive primary analysis of clinical and non clinical data to date PRIME Designation allows for frequent and early interactions with the EMA aimed at [...]
Progressive Care Inc. Issues 2018 Annual Report Conference Call Highlights
29/03/2019
MIAMI, March 29, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, today issued 2018 Annual Report Conference Call highlights. The Company [...]
Tyme Technologies Announces Pricing of its $12 Million Registered Offering
29/03/2019
NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) announced today that it has priced a registered offering of 8 million shares of its common stock, par value $0.0001 per share, and [...]
Cytori to Webcast Fourth Quarter and 2018 Financial Results on April 1
29/03/2019
SAN DIEGO, March 29, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year-end financial results and business update on Monday, April 1, 2019 at 8: [...]
Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
29/03/2019
CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
eFFECTOR Presents Data on its Selective Translation Regulators at AACR 2019 Annual Meeting
29/03/2019
SAN DIEGO, March 29, 2019 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that data from all three of [...]
Nephros to Present at the Spring Investor Summit on April 1st in New York City
29/03/2019
SOUTH ORANGE, NJ, March 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance liquid purification filters for both medical [...]
Entasis Therapeutics Reports Full Year 2018 Financial Results and Provides Business Update
29/03/2019
On track to commence two Phase 3 clinical trials in 2019 WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the [...]
Filing of Annual Report on Form 20-F
29/03/2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Files US Annual Report on Form 20-F Oxford, UK, and Cambridge, MA, US, 29 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader [...]
Auxly Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Outlook for 2019
29/03/2019
VANCOUVER, British Columbia, March 29, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (" Auxly " or the " Company ") today released its fourth quarter and full year 2018 financial results [...]
Axovant Announces Clinical Updates from AXO-AAV-GM2 and AXO-Lenti-PD Studies
29/03/2019
-R&D Day featuring leading physicians and scientists in Parkinson’s disease, GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs disease) will be webcast today at 8:30a.m. ET from New York- -Approximately 25% [...]
Emerald Health Therapeutics Delivers to Yukon and Adds Supply Agreements with Alberta and Saskatchewan
29/03/2019
VANCOUVER, British Columbia, March 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has fulfilled its first purchase order of cannabis from Yukon Liquor Corporation, [...]
ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
29/03/2019
Interim results support competitive efficacy, potential for monthly dosing and favourable safety profile SINGAPORE, March 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage [...]

Pages